Werewolf Therapeutics, Inc. (HOWL)

Werewolf Therapeutics' stock price has declined significantly in the past six months, reaching $0.87 as of November 21, 2025. Key events include Fast Track Designation for WTX-124, insider selling by MPM Asset Management-related entities, a Nasdaq compliance issue due to a vacancy on the audit committee, and an analyst price target adjustment by Citizens JMP from $4.00 to $3.00 with a Market Outperform rating.

There is no information available regarding demand seasonality for Werewolf Therapeutics, Inc.'s products or services. As a clinical-stage biopharmaceutical company, its current revenue streams are primarily related to research and development activities and funding, rather than commercial product sales, which typically exhibit seasonality.

Werewolf Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics that stimulate the immune system to fight cancer and other immune-mediated conditions. The company utilizes its PREDATOR™ platform to create INDUKINE™ molecules that selectively activate within the tumor microenvironment. Its pipeline includes WTX-124 for advanced or metastatic solid tumors (with Fast Track Designation for cutaneous melanoma), WTX-330 for advanced or metastatic solid tumors and lymphoma, JZP898 for cancer, WTX-921 for inflammatory bowel disease, WTX-712 for cancer, and WTX-518 for cancer.

Werewolf Therapeutics, Inc. is headquartered in Watertown, Massachusetts, United States. The information does not specify a broader international geographic footprint beyond its development activities.

Werewolf Therapeutics generally has a positive brand reputation among analysts, with a consensus rating of "Moderate Buy" or "Strong Buy". Analysts have an average 12-month price target ranging from $6.17 to $9.00, suggesting significant upside potential. However, the company's stock has underperformed both the US Biotechs industry and the broader US Market over the past year, which could negatively impact its reputation among investors. Recent insider selling and a Nasdaq compliance issue also pose minor reputational challenges.

Werewolf Therapeutics has a mixed ownership structure including institutional investors, insiders, and public/retail investors. Institutional shareholders hold approximately 31.45% to 43.49% of the stock, while insiders own between 23.60% and 93.50%. Retail investors hold around 0.00% to 13.65% of the stock. Major owners include Ra Capital Management, L.P., MPM Asset Management LLC, MPM BioVentures 2014, L.P., Vanguard Group Inc., Bank Of America Corp /de/, Ansbert Gadicke, Luke Evnin, and James E. Flynn. Insiders have sold more stock than they have bought in the past three months.